Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis
- PMID: 21200358
- DOI: 10.1097/PCC.0b013e3182070990
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis
Abstract
Objectives: A systematic literature review and meta-analysis was performed to evaluate the impact of prophylaxis with palivizumab on mortality and morbidity associated with respiratory syncytial virus infection in infants at high risk (≤ 35 wks of gestational age, chronic lung disease, or congenital heart disease).
Data sources: MEDLINE, EMBASE, and Current Contents were used. MEDLINE was searched from January 1, 1990 to May 16, 2007. The bibliographies of accepted studies and recent reviews and proceedings from the past 2 yrs were searched to identify additional relevant studies.
Study selection: Randomized controlled trials and prospective or retrospective cohort studies evaluating all-cause and respiratory syncytial virus-specific mortality, respiratory syncytial virus hospitalizations, and health care use in infants at high risk for respiratory syncytial virus infection receiving prophylaxis with palivizumab.
Data extraction: Data elements from each accepted study were extracted by one researcher and confirmed by a second researcher. Differences were resolved before data entry and analysis.
Data synthesis: A total of 2473 citations were screened and ten comparative studies of palivizumab prophylaxis evaluating >15,000 infants were included. Comparisons of mortality and hospitalization outcomes between infant groups using prophylaxis and not using prophylaxis were made using meta-analyses.
Conclusions: Prophylaxis and nonprophylaxis infant groups appeared to be comparable at baseline. All-cause mortality during the respiratory syncytial virus season was 12 of 6380 (0.19%) for infants with prophylaxis vs. 33 of 8182 (0.53%) for infants without prophylaxis (Peto odds ratio, 0.30; 95% confidence interval, 0.17-0.55). Only five respiratory syncytial virus-specific deaths were reported, and the majority of the studies did not report respiratory syncytial virus-related deaths. The rate of respiratory syncytial virus hospitalization was significantly lower among preterm infants with prophylaxis compared with those without prophylaxis (4.1% vs. 10.4%; odds ratio, 0.35; 95% confidence interval, 0.25-0.47). Prophylaxis with palivizumab was associated with a reduction in all-cause mortality and respiratory syncytial virus hospitalization among preterm infants at high risk. Additional research on cause of death among infants at high risk is needed.
Similar articles
-
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602. doi: 10.1002/14651858.CD006602.pub4. Cochrane Database Syst Rev. 2013. PMID: 23633336 Review.
-
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.Cochrane Database Syst Rev. 2014 May 22;(5):CD007743. doi: 10.1002/14651858.CD007743.pub5. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Jul 20;7:CD007743. doi: 10.1002/14651858.CD007743.pub6. PMID: 24851825 Updated. Review.
-
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.Cochrane Database Syst Rev. 2013 Jun 5;(6):CD007743. doi: 10.1002/14651858.CD007743.pub4. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2014 May 22;(5):CD007743. doi: 10.1002/14651858.CD007743.pub5. PMID: 23737087 Updated. Review.
-
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007743. doi: 10.1002/14651858.CD007743.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2013 Jun 05;(6):CD007743. doi: 10.1002/14651858.CD007743.pub4. PMID: 22336832 Updated. Review.
-
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. doi: 10.3310/hta12360. Health Technol Assess. 2008. PMID: 19049692 Review.
Cited by
-
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.BMC Infect Dis. 2024 Apr 19;24(1):418. doi: 10.1186/s12879-024-09300-5. BMC Infect Dis. 2024. PMID: 38641577 Free PMC article.
-
Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands.Vaccines (Basel). 2023 Dec 2;11(12):1807. doi: 10.3390/vaccines11121807. Vaccines (Basel). 2023. PMID: 38140212 Free PMC article.
-
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.Lancet Reg Health Am. 2023 Nov 9;28:100629. doi: 10.1016/j.lana.2023.100629. eCollection 2023 Dec. Lancet Reg Health Am. 2023. PMID: 38026446 Free PMC article.
-
New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus.Infect Drug Resist. 2023 Apr 8;16:2061-2074. doi: 10.2147/IDR.S379660. eCollection 2023. Infect Drug Resist. 2023. PMID: 37063935 Free PMC article. Review.
-
Human Respiratory Syncytial Virus Infections among Hospitalized Children in Poland during 2010-2020: Study Based on the National Hospital Registry.J Clin Med. 2022 Oct 31;11(21):6451. doi: 10.3390/jcm11216451. J Clin Med. 2022. PMID: 36362679 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous